



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: John D. Mountz et al.

Attorney Docket: UAB-11703/22

Serial No.: 10/776,119

Confirmation No. \_\_\_\_\_

Filed: February 10, 2004

Group Art No. \_\_\_\_\_

For: CONTROLLING IMMUNE RESPONSE TO SPECIFIC ANTIGENS

**INFORMATION DISCLOSURE STATEMENT**

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

Pursuant to Rule 97 and in compliance with Rule 56, Applicant hereby makes of record the items listed on the attached Form PTO-1449. Copies of the listed items were previously submitted in the prior related application, Serial No. 09/424,281 filed January 2, 2000.

None of these references disclose the inventive concepts claimed in the subject application.

Should there be a fee associated with this document, please charge it to Deposit Account No. 07-1180.


Respectfully submitted,


  
Avery N. Goldstein, Reg. No. 39,204  
Gifford, Krass, Groh, Sprinkle,  
Anderson & Citkowski, P.C.  
280 N. Old Woodward Ave., Suite 400  
Birmingham, MI 48009-5394  
(248) 647-6000

/jk

**CERTIFICATE OF MAILING**

I hereby certify that this paper or fee is being deposited with the United States Postal Services as first class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 23, 2004.

  
Janice R. Kuehn



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

UAB-11703/22

Application Number

10/776,119

Applicant(s)

John D. Mountz et al.

Filing Date

February 10, 2004

Group Art Unit

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,585,362	12/17/1996	Wilson et al.	514	44	
		5,658,776	08/19/1997	Flotte et al.	435	172.3	
		5,670,488	09/23/1997	Gregory et al.	514	44	

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Zhang et al. "Application of a Fas Ligand Encoding a Recombinant Adenovirus Vector for Prolongation of Transgene Expression" Journal of Virology, Vol. 72, No. 3, pp. 2483-2490 (March 1998).
		Mineta et al. "Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas" Nature Medicine, Vol. 1, No. 9, pp. 938-943 (September 1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>UAB-11703/22</b>	Application Number <b>10/776,119</b>
		Applicant(s) <b>John D. Mountz</b>	
		Filing Date <b>February 10, 2004</b>	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	Andreansky et al. "Evaluation of Genetically Engineered Herpes Simplex Viruses as Oncolytic Agents for Human Malignant Brain Tumors" Cancer Research 57, pp. 1502-1509 (April 15, 1997).
	Muruve et al. "Adenovirus-Mediated Expression of Fas Ligand Induces Hepatic Apoptosis after Systemic Administration and Apoptosis of Ex Vivo-Infected Pancreatic Islet Allografts and Isografts" Human Gene Therapy 8, pp. 955-963 (May 20, 1997).
	Rosenfeld et al. "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium" Cell, Vol. 68, pp. 143-155 (January 10, 1992).
	Connelly et al. "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice" Human Gene Therapy 6, pp. 185-193 (February 1995).
	Bellon et al. "Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial" Human Gene Therapy 8, pp. 15-25 (January 1, 1997).
	Connelly et al. "High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice" Human Gene Therapy 7, pp. 183-195 (January 20, 1996).
	Peng et al. "Construction of Recombinant Adeno-Associated Virus Vector Containing the Rat Preproinsulin II Gene" Journal of Surgical Research 69, 193-198 (1997).
	Wagner et al. "Toward Cystic Fibrosis Gene Therapy" Annu. Rev. Med. 48: 203-16 (1997).
	Sata et al. "Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response" Proc. Natl. Acad. Sci. USA, Vol. 9, pp. 1213-1217 (February 1998).
	Judge et al. "Functional analysis of a recombinant Fas ligand construct" Gastroenterology, Vol. 112, No. 4, p. A1007 (April 1997).
	Miller et al. "Targeted vectors for gene therapy" FASEB J. 9: 190-199 (1995).
	Verma et al. "Gene therapy-promises, problems and prospects" Nature Vol. 389: 239-242 (1997).

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>UAB-11703/22</b>	Application Number <b>10/776,119</b>
		Applicant(s) <b>John D. Mountz</b>	
		Filing Date <b>February 10, 2004</b>	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS	<i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
		Miller et al. "Targeted vectors for gene therapy" FASEB J. 9: 190-199 (1995).
		Verma et al. "Gene therapy-promises, problems and prospects" Nature Vol. 389: 239-242 (1997).
		Marshall "Gene Therapy's Growning Pains" Science Vol. 269: 1050-1055 (1995).
		Deonarain "Ligand-targeted receptor-mediated vectors for gene delivery" Exp. Opin. Ther. Patents 8(1); 53-69 (1998).
		Orkins et al. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" (1995)
EXAMINER		DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.